Flerie AB (publ) (STO:FLERIE)
Sweden
· Delayed Price · Currency is SEK | Market Cap | 2.28B |
| Revenue (ttm) | 1.80M |
| Net Income (ttm) | -567.30M |
| Shares Out | 83.22M |
| EPS (ttm) | -7.26 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 57,930 |
| Average Volume | 57,400 |
| Open | 27.40 |
| Previous Close | 27.30 |
| Day's Range | 26.80 - 27.60 |
| 52-Week Range | 26.80 - 47.70 |
| Beta | n/a |
| RSI | 22.19 |
| Earnings Date | Apr 15, 2026 |
About Flerie AB
Flerie AB (publ) is a venture capital firm specializing in early-stage investments. The firm seeks to invest in life science, biotech and pharma companies engaged in drug development and associated tools or applications tackling major medical challenges of our time. The firm seeks to invest in Europe, Nordic, United States and Israel. Flerie AB (publ) was founded in 2011 and is based in Stockholm, Sweden with additional office in London, United Kingdom. [Read more]
Financial Performance
In 2025, Flerie AB's revenue was 2.50 million, a decrease of -3.85% compared to the previous year's 2.60 million. Losses were -756.90 million, 232.0% more than in 2024.
Financial StatementsNews
Flerie AB Earnings Call Transcript: Q1 2026
Q1 2026 saw strong financing, raising SEK 208 million and boosting NAV to SEK 3.7 billion. The investment ratio reached 2.33x, with significant R&D progress and a completed Lipum merger, despite challenging market conditions.
Flerie AB Earnings Call Transcript: Q4 2025
Q4 saw a 14% NAV decline to SEK 3.4 billion, driven by write-downs in key holdings and strategic divestment of the LP segment. Management remains optimistic, citing strong clinical progress, robust cash reserves, and a focus on direct investments for long-term value creation.
Flerie AB Earnings Call Transcript: Q3 2025
NAV declined to SEK 3.9 billion in Q3, impacted by write-downs and share redemptions. Key portfolio milestones included successful capital raises, a merger, and new strategic partnerships, while market conditions showed early signs of recovery.
Flerie AB Earnings Call Transcript: Q2 2025
Celebrating its IPO anniversary, the company reported a SEK 4.1 billion NAV, strong cash position, and portfolio growth driven by clinical and commercial stage investments. Outperformed key indices despite a tough macro environment, with innovative M&A and capital management strategies.
Flerie AB Earnings Call Transcript: Q1 2025
Q1 saw a SEK 251 million NAV decline, driven by negative fair value changes, FX losses, and a full write-off of Provel Pharmaceuticals. Portfolio management included a premium divestment of A3P and a proposed Toleranzia merger, while maintaining strong liquidity and a 14% NAV discount.
Flerie AB Earnings Call Transcript: Q4 2024
NAV ended Q4 2024 at SEK 4.2 billion, down 1.5% sequentially, with strong co-investor leverage and significant new investments in AnaCardio, Chromafora, and Nanologica. Product development segment faced valuation declines, but cash position remains robust and a redemption program is in place.
Flerie AB Earnings Call Transcript: Q3 2024
NAV decreased to SEK 4.262 billion in Q3, with a -2.7% drop in NAV per share and a net loss of SEK 117 million. Portfolio value was impacted by listed company volatility, but strong cash reserves and a new share redemption scheme support future investments and liquidity.
Flerie AB Earnings Call Transcript: Q2 2024
Achieved Nasdaq Stockholm listing, raised SEK 1 billion, and grew NAV to SEK 4.4 billion, with a 2.1% adjusted NAV per share increase. Portfolio value rose, driven by gains in key holdings, and the company plans to deploy 10% of NAV annually, focusing on risk-mitigated biotech investments.